Context Therapeutics Reports Second Quarter 2025 Operating and Financial Results
Context Therapeutics (Nasdaq: CNTX), a clinical-stage biopharmaceutical company, reported Q2 2025 financial results and pipeline updates. The company maintains a strong financial position with $83.5 million in cash, expected to fund operations into 2027. Context is advancing two key clinical programs: CTIM-76 (CLDN6 x CD3 bispecific antibody) and CT-95 (MSLN x CD3 bispecific antibody), with initial data expected in 2026.
The company reported a net loss of $8.8 million for Q2 2025, with R&D expenses increasing to $7.8 million compared to $1.4 million in Q2 2024. Notable developments include the first patient dosed in the CT-95 Phase 1 trial and the appointment of Dr. Karen Chagin as Chief Medical Officer.
Context Therapeutics (Nasdaq: CNTX), un'azienda biofarmaceutica in fase clinica, ha comunicato i risultati finanziari del secondo trimestre 2025 e gli aggiornamenti sul pipeline. La società mantiene una solida posizione finanziaria con 83,5 milioni di dollari in contanti, sufficienti a finanziare le operazioni fino al 2027. Context sta portando avanti due programmi clinici chiave: CTIM-76 (anticorpo bispecifico CLDN6 x CD3) e CT-95 (anticorpo bispecifico MSLN x CD3), con i primi dati attesi nel 2026.
La società ha riportato una perdita netta di 8,8 milioni di dollari nel secondo trimestre 2025, con spese di R&S aumentate a 7,8 milioni di dollari rispetto a 1,4 milioni nel secondo trimestre 2024. Tra gli sviluppi rilevanti, il primo paziente trattato nello studio di fase 1 su CT-95 e la nomina della Dott.ssa Karen Chagin a Chief Medical Officer.
Context Therapeutics (Nasdaq: CNTX), una empresa biofarmacéutica en etapa clínica, informó los resultados financieros del segundo trimestre de 2025 y actualizaciones de su pipeline. La compañía mantiene una sólida posición financiera con 83,5 millones de dólares en efectivo, que se espera financien las operaciones hasta 2027. Context está avanzando en dos programas clínicos clave: CTIM-76 (anticuerpo bispecífico CLDN6 x CD3) y CT-95 (anticuerpo bispecífico MSLN x CD3), con datos iniciales previstos para 2026.
La empresa reportó una pérdida neta de 8,8 millones de dólares en el segundo trimestre de 2025, con gastos de I+D que aumentaron a 7,8 millones de dólares en comparación con 1,4 millones en el segundo trimestre de 2024. Entre los desarrollos importantes se incluye el primer paciente dosificado en el ensayo de fase 1 de CT-95 y el nombramiento de la Dra. Karen Chagin como Chief Medical Officer.
Context Therapeutics (나스닥: CNTX)는 임상 단계의 바이오제약 회사로서 2025년 2분기 재무 결과 및 파이프라인 업데이트를 발표했습니다. 회사는 8,350만 달러 현금을 보유하고 있어 2027년까지 운영 자금을 확보한 강력한 재무 상태를 유지하고 있습니다. Context는 두 가지 주요 임상 프로그램인 CTIM-76 (CLDN6 x CD3 이중특이성 항체)과 CT-95 (MSLN x CD3 이중특이성 항체)를 진행 중이며, 초기 데이터는 2026년에 발표될 예정입니다.
회사는 2025년 2분기에 880만 달러 순손실을 보고했으며, 연구개발비는 2024년 2분기의 140만 달러에서 780만 달러로 증가했습니다. 주요 성과로는 CT-95 1상 시험에서 첫 환자 투여 완료와 Dr. Karen Chagin의 최고의료책임자(CMO) 임명이 포함됩니다.
Context Therapeutics (Nasdaq : CNTX), une société biopharmaceutique en phase clinique, a publié ses résultats financiers du deuxième trimestre 2025 ainsi que des mises à jour sur son pipeline. L'entreprise dispose d'une solide position financière avec 83,5 millions de dollars en liquidités, ce qui devrait financer ses opérations jusqu'en 2027. Context fait progresser deux programmes cliniques clés : CTIM-76 (anticorps bispécifique CLDN6 x CD3) et CT-95 (anticorps bispécifique MSLN x CD3), avec des données initiales attendues en 2026.
L'entreprise a enregistré une perte nette de 8,8 millions de dollars au deuxième trimestre 2025, avec des dépenses en R&D en hausse à 7,8 millions de dollars contre 1,4 million au deuxième trimestre 2024. Parmi les développements notables figurent la première administration à un patient dans l'essai de phase 1 de CT-95 et la nomination du Dr Karen Chagin au poste de Chief Medical Officer.
Context Therapeutics (Nasdaq: CNTX), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, berichtete über die Finanzergebnisse des zweiten Quartals 2025 und Neuigkeiten zur Pipeline. Das Unternehmen verfügt über eine starke finanzielle Position mit 83,5 Millionen US-Dollar in bar, die voraussichtlich die Geschäftstätigkeit bis 2027 finanzieren werden. Context entwickelt zwei wichtige klinische Programme weiter: CTIM-76 (CLDN6 x CD3 bispezifischer Antikörper) und CT-95 (MSLN x CD3 bispezifischer Antikörper), wobei erste Daten für 2026 erwartet werden.
Das Unternehmen meldete einen Nettoverlust von 8,8 Millionen US-Dollar für das zweite Quartal 2025, wobei die F&E-Ausgaben auf 7,8 Millionen US-Dollar im Vergleich zu 1,4 Millionen im zweiten Quartal 2024 gestiegen sind. Zu den bemerkenswerten Entwicklungen zählen die Dosierung des ersten Patienten in der Phase-1-Studie zu CT-95 und die Ernennung von Dr. Karen Chagin zur Chief Medical Officer.
- Strong cash position of $83.5 million providing runway into 2027
- Progress in clinical pipeline with two ongoing Phase 1 trials
- First patient dosed in CT-95 Phase 1 trial for multiple solid tumors
- Strategic appointment of new Chief Medical Officer strengthening leadership team
- Increased net loss to $8.8 million from $2.3 million year-over-year
- Significant rise in R&D expenses to $7.8 million from $1.4 million year-over-year
- Cash decreased from $94.4 million to $83.5 million since December 2024
Insights
Context Therapeutics reports strong $83.5M cash position funding operations into 2027 while advancing three cancer immunotherapy candidates in clinical development.
Context Therapeutics' Q2 2025 results reveal a solid financial foundation with
The company's R&D expenses increased substantially to
Context's lead candidate CTIM-76 (targeting Claudin 6) and CT-95 (targeting mesothelin) are both in Phase 1 dose-escalation studies with data readouts expected by mid-2026. Additionally, the company plans to initiate a first-in-human trial for CT-202 (targeting Nectin-4) in Q2 2026. These three distinct tumor targets represent a diversified approach to solid tumor immunotherapy.
The
Context's approach targeting solid tumors with T cell engagers addresses a significant unmet need, as most approved bispecific antibodies currently target hematological malignancies. The quarterly results demonstrate disciplined execution of the company's clinical development strategy while maintaining financial stability.
CTIM-76 and CT-95 Phase 1 dose-escalation studies ongoing
Cash and cash equivalents of
Company expects its cash and cash equivalents will continue to fund operations into 2027
PHILADELPHIA, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced its financial results for the second quarter ended June 30, 2025, and reported on recent and upcoming business highlights.
“We remain focused on progressing our clinical pipeline — CTIM-76, a selective Claudin 6 (“CLDN6”) x CD3 bispecific antibody, and CT-95, an avidity enhanced mesothelin (“MSLN”) x CD3 bispecific antibody,” said Martin Lehr, CEO of Context. “We expect to share initial dose escalation data for the CTIM-76 trial in the second quarter of 2026 and for the CT-95 trial by mid-2026.”
“We also expect to complete necessary regulatory filings to support the initiation of a first-in-human trial for CT-202, a potential best-in-class Nectin-4 x CD3 bispecific antibody, in the second quarter of 2026,” Mr. Lehr continued. “With cash runway into 2027, we believe we are well-positioned to achieve our goal of advancing our portfolio of innovative T cell-engaging therapies for solid tumors.”
Second Quarter 2025 Highlights
Pipeline Updates
- In June 2025, presented a Trial in Progress poster for the Phase 1 clinical trial evaluating CTIM-76 at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
- In April 2025, presented preclinical and translational data for CT-95, a MSLN targeting T cell engager, at the American Association for Cancer Research (AACR) Annual Meeting 2025.
- In April 2025, announced the first patient dosed in our Phase 1 clinical trial evaluating CT-95 in patients with MSLN-expressing advanced solid tumors, including ovarian, pancreatic, lung, and mesothelioma cancers.
Corporate Updates and Presentations
- In June 2025, announced the appointment of Dr. Karen Chagin as Chief Medical Officer
- In May 2025, presented at the Citizens Life Sciences Conference.
- In April 2025, participated in the 24th Annual Needham Virtual Healthcare Conference.
Second Quarter 2025 Financial Results
- Cash and cash equivalents were
$83.5 million at June 30, 2025, compared to$94.4 million at December 31, 2024. The Company expects its cash and cash equivalents will be sufficient to fund its operations into 2027. - Research and development (“R&D”) expenses were
$7.8 million for the second quarter of 2025, as compared to$1.4 million for the second quarter of 2024. The increase in R&D expenses was primarily driven by higher CT-202 expense of$3.1 million , higher CT-95 expense of$1.5 million and higher CTIM-76 expense of$0.1 million . CT-95 was acquired in July 2024 and CT-202 was in-licensed in September 2024. In addition, personnel-related costs increased by$1.6 million primarily due to higher headcount over the prior year period as well as termination benefits incurred related to employee departures. - General and administrative expenses were
$1.9 million for the second quarter of 2025, as compared to$1.7 million for the second quarter of 2024. The increase was primarily driven by a$0.2 million increase in personnel-related costs, including share-based compensation, mainly due to higher headcount and compensation adjustments. - Other income was approximately
$0.9 million for the second quarter of 2025, as compared to other income of$0.8 million for the second quarter of 2024, primarily due to higher interest income earned on cash and cash equivalent balances. - Context reported a net loss of
$8.8 million for the second quarter of 2025, as compared to a loss of$2.3 million for the second quarter of 2024.
About Context Therapeutics®
Context Therapeutics Inc. (Nasdaq: CNTX) is a biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors. Context is building an innovative portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 x CD3 TCE, CT-95, a Mesothelin x CD3 TCE, and CT-202, a Nectin-4 x CD3 TCE. Context is headquartered in Philadelphia. For more information, please visit www.contexttherapeutics.com or follow the Company on X (formerly Twitter) and LinkedIn.
Forward-looking Statements
This press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, included in this press release regarding strategy, future operations, prospects, plans and objectives of management, including words such as “may,” “will,” “expect,” “anticipate,” “look forward,” “plan,” “intend,” and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are forward-looking statements. These include, without limitation, statements regarding (i) our expectation to share initial dose escalation data from the Phase 1 trials of CTIM-76 and CT-95 in the second quarter of 2026 and mid-2026, respectively, (ii) our expectation to complete necessary regulatory filings to support the initiation of a first-in-human trial for CT-202 in the second quarter of 2026, (iii) having sufficient cash and cash equivalents to fund our operations into 2027, (iv) the potential benefits, characteristics, and side effect profile of our product candidates, (v) the ability of our product candidates to have benefits, characteristics, and a side effect profile that is differentiated and/or better than third party product candidates, (vi) the likelihood data will support future development, and (vii) the likelihood of obtaining regulatory approval of our product candidates. Forward-looking statements in this release involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, and we therefore cannot assure you that our plans, intentions, expectations, or strategies will be attained or achieved. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in our filings with the U.S. Securities and Exchange Commission, including the section titled “Risk Factors” contained therein. Except as otherwise required by law, we disclaim any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events, or circumstances or otherwise.
| Context Therapeutics Inc. | |||||||||||||||
| Condensed Statements of Operations | |||||||||||||||
| (Unaudited) | |||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||||
| Operating Expenses | |||||||||||||||
| Research and development | $ | 7,830,544 | $ | 1,384,553 | $ | 11,293,535 | $ | 3,357,762 | |||||||
| General and administrative | 1,927,818 | 1,703,996 | 3,993,970 | 3,554,288 | |||||||||||
| Loss from operations | (9,758,362 | ) | (3,088,549 | ) | (15,287,505 | ) | (6,912,050 | ) | |||||||
| Other income | 930,852 | 834,043 | 1,882,734 | 989,747 | |||||||||||
| Net loss | $ | (8,827,510 | ) | $ | (2,254,506 | ) | $ | (13,404,771 | ) | $ | (5,922,303 | ) | |||
| Net loss per common share, basic and diluted | ( | ) | ( | ) | ( | ) | ( | ) | |||||||
| Weighted average shares outstanding, basic and diluted | 95,186,935 | 54,958,635 | 95,186,935 | 35,462,344 | |||||||||||
| Context Therapeutics Inc. | |||||||||||||||
| Condensed Balance Sheets Data | |||||||||||||||
| (Unaudited) | |||||||||||||||
| June 30, | December 31, | ||||||||||||||
| 2025 | 2024 | ||||||||||||||
| Cash and cash equivalents | $ | 83,517,047 | $ | 94,429,824 | |||||||||||
| Other assets | 3,635,054 | 3,696,935 | |||||||||||||
| Total assets | $ | 87,152,101 | $ | 98,126,759 | |||||||||||
| Total liabilities | $ | 4,607,779 | $ | 2,860,497 | |||||||||||
| Total stockholders' equity | 82,544,322 | 95,266,262 | |||||||||||||
| Total liabilities and stockholders' equity | $ | 87,152,101 | $ | 98,126,759 | |||||||||||
Investor Relations Contact:
Jennifer Minai-Azary
Context Therapeutics
IR@contexttherapeutics.com
FAQ
What is Context Therapeutics' (CNTX) current cash position and runway?
How much did Context Therapeutics' (CNTX) R&D expenses increase in Q2 2025?
What are the key clinical programs in Context Therapeutics' pipeline?
When will Context Therapeutics (CNTX) report initial data from its clinical trials?
What was Context Therapeutics' (CNTX) net loss in Q2 2025?
